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Abstract
Background: A large fraction of murine tumors induced by transgenic expression of SV40 large T antigen (SV40 TAg)
exhibits a neuroendocrine phenotype. It is unclear whether SV40 TAg induces the neuroendocrine phenotype by
preferential transformation of progenitor cells committed to the neuroendocrine lineage or by transcriptional activation of
neuroendocrine genes.
Methodology/Principal Findings: To address this question we analyzed CEA424-SV40 TAg-transgenic mice that develop
spontaneous tumors in the antral stomach region. Immunohistology revealed expression of the neuroendocrine marker
chromogranin A in tumor cells. By ELISA an 18-fold higher level of serotonin could be detected in the blood of tumor-
bearing mice in comparison to nontransgenic littermates. Transcriptome analyses of antral tumors combined with gene set
enrichment analysis showed significant enrichment of genes considered relevant for human neuroendocrine tumor biology.
This neuroendocrine gene signature was also expressed in 424GC, a cell line derived from a CEA424-SV40 TAg tumor,
indicating that the tumor cells exhibit a similar neuroendocrine phenotype also in vitro. Treatment of 424GC cells with SV40
TAg-specific siRNA downregulated expression of the neuroendocrine gene signature.
Conclusions/Significance: SV40 TAg thus appears to directly induce a neuroendocrine gene signature in gastric carcinomas
of CEA424-SV40 TAg-transgenic mice. This might explain the high incidence of neuroendocrine tumors in other murine SV40
TAg tumor models. Since the oncogenic effect of SV40 TAg is caused by inactivation of the tumor suppressor proteins p53
and RB1 and loss of function of these proteins is commonly observed in human neuroendocrine tumors, a similar
mechanism might cause neuroendocrine phenotypes in human tumors.
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Introduction
A number of different strategies have been adopted to create
transgenic murine tumor models which mirror human malignant
disease.One strategyincludesthe useofoncogenesthe expression of
which is driven by tissue-specific promoters. Simian virus 40 large
T antigen (SV40 TAg) is commonly employed as an oncogene to
reliably elicit tumors in transgenic mice due to its capability to
simultaneously inactivate p53 and retinoblastoma (RB) proteins
(pRB, p107, p130), prominent cellular tumor suppressors. Inacti-
vation of the RB proteins leads to loss of suppression of a family of
E2F transcription factors which in turn induce expression of cell
cycle-promoting genes. In addition, inactivation of p53 switches off
genes which encode apoptosis-inducing proteins thus allowing
quiescent cells to re-enter S-phase and to escape apoptosis [1]. In
that way a large panel of transgenic mouse strains has been
established which develop tumors in a wide spectrum of organs, e.g.
colon, stomach, prostate, pancreas and lung [2,3]. Surprisingly, the
majority of SV40 TAg-induced tumors exhibit a neuroendocrine
phenotype [4,5,6,7,8,9]. In contrast, in humans neuroendocrine
tumors represent only a minor fraction accounting for some 1–3%
of all tumors [10]. Neuroendocrine tumors are supposed to be of
neuroectodermal origin and possess properties typical of neuroen-
docrine cells, like containing secretory granules, producing
neuroendocrine factors including chromogranin, synaptophysin
and specific hormones [11].
We have previously established a transgenic mouse strain which
expresses SV40 TAg under the control of a human carcinoem-
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[12]). Those mice develop with 100% penetrance antral stomach
tumors at an early age and die from the tumor at an age of about
115 days. Based on the expression of the epithelial marker
EpCAM in derived tumor cell lines and transgenic human CEA
which is widely expressed in mucus-producing epithelial cells and
adenocarcinomas we tentatively classified these tumors as
adenocarcinomas [12,13,14]. The undifferentiated nature of
CEA424-SV40 TAg tumors and the high incidence of neuroen-
docrine tumors among SV40 TAg-induced tumors, however,
prompted us to reinvestigate the gastric tumors of CEA424-SV40
TAg mice. Indeed, transcriptome, immunohistological and
electron microscopic analysis revealed typical neuroendocrine
features of these tumors.
From this the question arises whether SV40 TAg is directly
responsible for expression of the genes encoding the neuroendo-
crine proteins. To answer this question, we downregulated by
siRNA the expression of SV40 TAg in 424GC tumor cells, a cell
line which was generated from a primary tumor of CEA424-SV40
TAg-transgenic mice [13] and determined the transcriptome of
treated and non-treated cells. As expected, we observed down-
regulation of genes which are activated by E2F transcription
factors. Upon silencing of SV40 TAg mRNA, the SV40 TAg can
no longer inhibit the RB protein, itself a repressor of E2F proteins.
Surprisingly, gene set enrichment analysis (GSEA) revealed that a
group of genes characteristically expressed in human neuroendo-
crine tumors were also significantly downregulated. These findings
might explain the often observed association of SV40 TAg
transgenesis and neuroendocrine tumor formation.
Results
CEA424-SV40 TAg gastric tumors exhibit a
neuroendocrine phenotype
In order to reinvestigate the previous classification of CEA424-
SV40 TAg tumors as adenocarcinomas [12] we performed
genome-wide expression analyses with RNA from the antral
region from normal and tumor-bearing mice. Stomachs from 30-,
60- and 90-day-old mice were analyzed. At day 30 (d30), CEA424-
SV40 TAg-transgenic mice exhibit small multifocal tumor lesions
in the pyloric region of the antrum (Figure 1 H, inset) which grow
exponentially leading to extended tumors at an age of 90 days
which infiltrate into the duodenum and cause death within a
further 2–3 weeks probably by pyloric stenosis (Figure 1 D). Four,
27 and 338 probe sets/genes were found to be more than 5-fold
expressed in tumor-bearing antral regions from 30, 60 and 90 day
old transgenic mice, respectively, when compared to antra from
normal littermates (Figure 1 A–C). 272 of the genes upregulated
.5-fold in the stomachs of 90 day old transgenic mice were
overexpressed at a significance level of p,0.05 (Table S1).
Interestingly, a substantial fraction of the most highly expressed
and most strongly upregulated genes comprised genes character-
istic for the neuroendocrine lineage, e.g. genes encoding
chromogranin B (Chgb), secretin (Sct), glucagon (Gcg), secretogranin
II (Scg2) and tryptophan hydroxylase (Tph1) (Figure 1 A–C; Table
S2). This finding was substantiated using gene set enrichment
analyses (GSEA) by comparing the d90 tumor versus normal tissue
ranked gene list with a list of 399 genes preferentially expressed
after transdifferentiation of ATP4B-expressing gastric preparietal
progenitor cells (pPC), without neuroendocrine features, into
locally invasive or metastatic neuroendocrine tumor cells (iGC/
mGC) in gastric tumors of Atp4b promoter-SV40 TAg-transgenic
mice (Table 5 in [4]). This list of mouse genes overlaps with genes
that were found to be typically expressed in human neuroendo-
crine lung cancers [4]. In addition, a list of 52 genes assembled by
Hofsli et al. (Table 3 in [15]) which are characteristically expressed
in human neuroendocrine tumors and are thought to play a role in
neuroendocrine tumor biology was used to determine selective
enrichment of ‘‘neuroendocrine tumor genes’’ in CEA424-SV40
TAg tumors. Most significantly, both sets of genes were highly
enriched in the group of genes upregulated in tumors of 90-day-
old mice exhibiting low false discovery rates (FDR) at a high
significance level (p,0.001; Figure 1 E, F; Table 1).
In order to see whether overexpression of Tph1 in d90 tumor
tissue (Figure 1 C; Table S1) translates into higher serotonin blood
levels in tumor-bearing mice, we measured serotonin serum
concentrations in wildtype and CEA424-SV40 TAg-transgenic
mice using ELISA. Tryptophan hydroxylase catalyzes the rate-
limiting step in the conversion of L-tryptophan to serotonin with 5-
hydroxy-L-tryptophan as an intermediate product. In sera of
transgenic tumor-bearing mice 18-fold higher serotonin levels
were found (Figure 1 G).
Expression of Chga mRNA was 15-fold upregulated in d90
tumors in comparison to normal antrum (Table S1). Upregulation
could be confirmed at the protein level by immunohistology. Most
of the tumor cells which were identified by nuclear expression of
SV40 TAg in parallel tissue sections of 30- and 90-day-old
CEA424-SV40 TAg-transgenic mice (Figure 1 H, I) strongly
expressed chromogranin A (Figure 1 J, K). Double-labeling with
fluorescent antibodies corroborated coexpression of SV40 TAg
and CHGA in a large fraction of SV40 TAg-positive tumor cells
in d30 and d60 tumors (Figure 1M, N). Furthermore, elec-
tron microscopy (Figure 1 L) revealed numerous electron-dense
secretory granules in the cytoplasm of tumor cells which are
characteristically observed in neuroendocrine cells [4]. Two
different size classes could be discriminated: the small probably
represent so called synaptic-like microvesicles (SLMV) and the
larger granules large dense core vesicles (LDCV) which are known
to contain synaptophysin and chromogranin A, respectively [16].
To check whether SV40 TAg is also expressed in gastric
epithelial progenitors, we costained gastric tissue sections from 30-,
60- and 90-day-old CEA424-SV40 TAg mice with an acid mucin-
detecting dye (Alcian blue) and anti-SV40 TAg antibodies. No
Alcian blue staining was observed in SV40 TAg-positive cells. Less
than 5% of TAg-positive cells were found in close vicinity of Alcian
blue-stained cells in 30-day-old mice (Figure S1).
In order to identify regulatory proteins which might be
responsible for the development of the neuroendocrine phenotype
we looked at the expression of a subset of 32 genes from the 399
member gene list compiled by Syder et al. (Table 7 in [4]). These
genes encode transcription factors and DNA-binding proteins.
Out of this list, 31 could be identified in our probe sets. Twenty-
three out of these 31 genes were clearly expressed (.100 RFU).
Transcripts of 16 of these genes (52%) were significantly (p,0.05)
enriched in the d90 tumors compared to normal antral tissues
(Table S3). Notably, among the most highly enriched transcripts
were those of Nkx2.2 and Neurod1 that encode transcription factors
known to be involved in the differentiation of the neuroendocrine
lineage of gastrointestinal tissues [17]. NEUROD1 protein could
be detected by Western blot in tumors from 85-day-old mice as
well as in cell lines established from CEA424-SV40 TAg gastric
tumors (Figure 1 O). In contrast, suppressors of the enteroendo-
crine lineage, HES1 and GFI1 which inhibit the activators of the
enteroendocrine lineage ATOH1 and NEUROG3, respectively,
are either not expressed (Gfi1) or depleted (Hes1; 1.5-fold; data not
shown). mRNAs of transcription factors genes which support the
formation of other intestinal lineages, like Sox9 (Paneth cells), Klf4
(goblet cells) and Elf3 (goblet cells and enterocytes) are depleted in
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PLoS ONE | www.plosone.org 2 January 2012 | Volume 7 | Issue 1 | e29846Figure 1. CEA424-SV40 TAg gastric tumors exhibit a neuroendocrine phenotype. Transcriptome analysis of RNA from tumor-bearing
regions of the antrum from 30- (A), 60- (B) and 90-day-old CEA424-SV40 TAg-transgenic mice (C) and non-transgenic mice revealed predominant
enrichment of genes typically expressed in neuroendocrine tissues (symbols shown in green). The means of the expression levels of genes
preferentially expressed in tumor-bearing stomach tissues were plotted against their expression ratio tumor/normal stomach (genes with fold change
.5-fold are shown; n=3). The most strongly upregulated and most highly expressed genes in the samples are identified by gene symbols. These
were statistically significant for day 90 (p,0.05). Note the strong increase of upregulated genes with age which reflects the exponential tumor
growth between d30 and d90 in CEA424-SV40 TAg transgenic mice (D). (E, F) Gene set enrichment analysis (GSEA) of the d90 tumor ranked gene list
using the neuroendocrine signature genes from murine Atp4b-SV40 TAg gastric tumors ([4]; E) and from human neuroendocrine tumors ([15]; F)
comprising 305 identifiable genes out of 399 genes and 39 identifiable genes out of 52 genes, respectively. ES, enrichment score; FDR, false discovery
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Interestingly, the gene encoding the transcription factor ETV1
which has recently been shown to represent a master regulator in
gastrointestinal stromal (GIST) tumors is strongly expressed and its
transcripts are more than 17-fold enriched in d90 tumors (Table
S1, Table S3). GIST tumors are thought to be derived from
intestinal interstitial cells of Cajal (ICC), a neuronal cell lineage
[18].
The CEA424-SV40 TAg gastric tumor-derived cell line
424GC transcriptome reflects the neuroendocrine
phenotype of the parental tumor
A number of cell lines have been derived from primary gastric
tumors of CEA424-SV40 TAg-transgenic mice [13]. Previous
analyses of these cell lines were not aimed at the characterization
of their potential neuroendocrine phenotype. Therefore, we
compared the transcriptome of 424GC cells with that of the
antral regions of 30-, 60-, 90-day-old CEA424-SV40 TAg-
transgenic as well as of non-transgenic mice by hierarchical
clustering and principal component (PCA) analysis. As expected,
the antral stomach regions from normal, 30-day-and 60-day-old
transgenic mice which have a very small tumor load (Figure 1 D)
cluster together whereas d90 tumors differ substantially from that
of normal tissue and are more similar to 424GC tumor cells
(Figure 2 A). Similar results were obtained when performing PCA
(Figure 2 B). In PCA the expression differences of various samples
are condensed into one data point and displayed in a three
dimensional coordinate system. Samples which exhibit similar
expression pattern are found in close proximity. The cluster
heatmap reveals several genes with high expression in d90 tumors
and 424GC tumor cells in comparison to all other samples. The
relationship of d90 tumors and 424GC transcriptomes was further
exemplified by comparing the expression levels of genes which
were more than 15-fold enriched in d90 tumors in comparison to
normal antrum (Figure 2 C). Most strikingly, high expression at a
similar level of genes encoding characteristic neuroendocrine
lineage markers, like secretin (Sct), chromogranin B (Chgb),
tryptophan hydroxylase 1 (Tph1), regulated endocrine-specific
protein of 18 kDa (Resp18), synaptosomal associated 25 kDa
protein (Snap25), secretogranin II (Scg2) and glucagon (Gcg), was
found both in d90 tumors and 424GC cells.
SV40 T antigen-specific siRNA downregulates expression
of neuroendocrine genes in CEA424-SV40 TAg gastric
cancer cell line
Because murine tumors induced by transgenic expression of
SV40 TAg often exhibit a neuroendocrine phenotype we reasoned
that knock-down of SV40 TAg by siRNA in SV40 TAg-positive
rate; tumor up/down, signature gene sets up- or downregulated in tumors. (G) Tumor-bearing transgenic mice exhibit elevated serum serotonin
levels. Serum from wildtype (n=6 pooled; age: 130 d) and CEA424-SV40 TAg mice (n=6; age: 95–110 d) were analyzed by ELISA. (H–K) Gastric tumor
cells express both SV40 TAg (brown nuclear staining; H, I) and the neuroendocrine marker chromogranin A (CHGA; brown cytoplasmic staining; J, K).
Parallel sections of formalin-fixed paraffin-embedded gastric tumors from 30- and 99-day-old mice were used for immunohistological staining. The
tumors were localized in the antrum and duodenum, respectively. Latter tumors were commonly observed in mice older than 90 days and are
supposed to have originated from pyloric tumors through invasive growth or metastatic spread. (M, N) Double-staining with fluorescently labeled
anti-SV40 TAg and CHGA of gastric tumor-bearing tissue from 30- and 60-day-old mice. Note most of the cells with SV40 TAg-positive nuclei (red
color) express CHGA (yellow color). The nuclei are visualized by DAPI (blue color). Bars: 50 mm. (L) Transmission EM of a typical tumor cell in a tumor
from a 90-day-old CEA424-SV40 TAg mouse. Note the numerous electron-dense secretory granules (LDCV, large dense core vesicles, arrows; SLMV,
small synaptic-like microvesicles arrowheads) and extended mesh of rough endoplasmic reticulum (ER; open arrowheads) typical of neuroendocrine
and rapidly growing cells, respectively. Original magnification: 615.300 in (L). Bars: 50 mm in H-K; 2 mm in L. (O) Western blot analysis of NEUROD1
expression in CEA424-SV40 TAg tumor-derived cell lines (424GC, GC3, GC8) and in tumors from 85-day-old mice. The endothelioma cell line served as
a negative control, detection of b-actin as loading control.
doi:10.1371/journal.pone.0029846.g001
Table 1. Gene set enrichment analyses (GSEA) of transcriptomes of d90 CEA424-SV40 TAg tumors and of 424GC cells after SV40
TAg siRNA treatment using neuroendocrine and E2F target gene signatures.
Sample Gene set
Number of applicable
gene sets (total) Enrichment score (ES) p value
1
False discovery
rate (FDR)
d90 gastric tumors Syder
2 305 (399) 20.800 ,0.001 0.090
424GC Syder
2 256 (399) 20.443 0.481 0.657
d90 gastric tumors Syder (transcription factors)
3 25 (32) 20.860 ,0.001 0.112
424GC Syder (transcription factors)
3 25 (32) 20.657 0.402 0.585
d90 gastric tumors Hofsli
4 39 (52) 20.757 ,0.001 0.120
424GC Hofsli
4 36 (52) 0.858 ,0.001 0.125
d90 gastric tumors Schaffer
5 19 (23) 20.898 ,0.001 0.081
424GC Schaffer
5 23 (23) 0.853 ,0.001 0.180
d90 gastric tumors Cantalupo
6 (E2F) 38 (42) 20.689 0.184 0.261
424GC Cantalupo
6 (E2F) 39 (42) 0.883 ,0.001 0.147
1p values,0.001 in bold;
2Syder et al. 2004, Table S5 [4];
3Syder et al. 2004, Table S7 [4];
4Hofsli 2006, Table 3 [15];
5Schaffer et al. 2010, Figure 4a [30];
6Cantalupo et al. 2009, Table S5 [19].
doi:10.1371/journal.pone.0029846.t001
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expression of neuroendocrine genes. To this end we designed
three different SV40 TAg-specific siRNAs and tested their ability
to diminish SV40 TAg mRNA expression 72 h after transfection
of 424GC cells. Both siRNA82 and siRNA2047 abrogated SV40
TAg mRNA expression completely as judged by reverse trans-
cription polymerase chain reaction analysis (Figure 3 A). The
silencing potency of siRNA82 was further analyzed by Western
blot analysis. Seventy-two hours after siRNA transfection only
marginal amounts of SV40 TAg protein could be detected
(Figure 3 B).
We then analyzed the transcriptome of 424GC cells treated for
72 h with siRNA82 using oligonucleotide microarrays which
included probe sets for SV40 TAg mRNA and compared it to that
of untreated cells. The siRNA treatment led to a reduction of the
level of SV40 TAg mRNA by 56% (p,0.01). The expression of
genes encoding ribosomal proteins which we assumed to be
unaffected by siRNA82 treatment varied maximally ,2-fold (up
or down; mean fcwith/without siRNA=1.0760.25) between the two
samples (Figure 3 C green dots). Therefore, we considered a .2-
fold change in mRNA levels as biologically relevant. SiRNA
treatment of 424GC cells downregulated the expression of 269
genes/gene sets .2-fold, while 238 genes/gene sets showed a .2-
fold upregulation (Figure 3 C; Table S4).
Not surprisingly, among the genes that were most strongly
downregulated by treatment with SV40 TAg-specific siRNA (2.8–
4.1-fold), were those that were frequently found to be involved in
proliferation and cell cycle progression such as Eif4g2 (eukaryotic
translation initiation factor 4, gamma 2), Ccnb1 (cyclin B1), Pcna
(proliferating cell nuclear antigen) and Mki67 (antigen identified by
monoclonal antibody Ki67) (Table S4). Concomitantly, genes
encoding cell cycle inhibitors and apoptosis-promoting proteins
were upregulated (2.2–2.5-fold), among them Cdkn2b (cyclin-
dependent kinase inhibitor 2B), Pdcd4 (programmed cell death 4)
and Bax (Bcl2-associated X protein) (Figure 3 C; Table S4). Many
of the downregulated genes represent target genes of E2F
transcription factors which are activated through the silencing of
the RB protein by SV40 TAg [1]. Indeed, GSEA analysis of the
ranked gene list obtained from siRNA-treated and untreated cells
using a set of E2F target genes which was compiled by Cantalupo
et al. [19] revealed a highly significant enrichment (p,0.01) of
E2F target genes in the downregulated fraction (Figure 3 D;
Table 1).
Notably, we observed also downregulation by SV40 TAg
siRNA of genes encoding neuroendocrine markers (Figure 3 C;
Table S4) like Gnas (3.5-fold), Pdyn (prodynorphin) (3.3-fold), Chga
(3-fold), Gcg (2.4-fold) as well as Scg2 and Sst (2.3-fold each). No
neuroendocrine marker genes were significantly upregulated
by SV40 TAg siRNA with the exception of Calca (2.7-fold)
(calcitonin/calcitonin-related polypeptide alpha) (Figure 3 C;
Table S4). These findings were corroborated by GSEA analyses
which revealed significant enrichment (p,0.01) of genes selectively
expressed in human endocrine tumors (Figure 3 E; Table 1) [15].
Furthermore, the highly expressed gene Hey1 (hairy/enhancer-of-
split-related with YRPW motif) which induces neuronal differentiation
in the brain and represents a bona fide E2F target gene [20] was
significantly transcriptionally downregulated (2-fold; p,0.01) in
424GC cells by TAg-specific siRNA (data not shown). On the
other hand, none of the transcription factor genes which regulate
the neuroendocrine lineage like Nkx2.2 and Neurod1 was signifi-
cantly downregulated by TAg siRNA (data not shown).
To our surprise, the most strongly downregulated genes
represented endogenous retroviral genes (Mela, MSV, Abl-MLV;
Figure 3 C; Table S4). Regulation of endogenous retroviruses by
SV40 TAg has been noted before and might be explained by
direct transcriptional activation by TAg of promoter elements
within retroviral long terminal repeats [21].
Discussion
The SV40 TAg has been used for the induction of numerous
organ-specific cancer models in transgenic mice, through control
of its expression by a large variety of cell type-specific promoters
[2]. Surprisingly, a large proportion of the published models
(,70%) express markers that are typically found in neuroendo-
crine tumors (Table S5, Supporting References S1), like peptide
hormones (gastrin, gastrin-releasing peptide, somatostatin, gluca-
gon), proteins stored in specific secretory granules (chromogranin
A and B, synaptophysin) and neuroamines (serotonin, dopamine).
Some of these substances are responsible for often severe
symptoms such as flushing, diarrhea and dermatitis noticed in
patients with certain neuroendocrine tumors [10]. In the model
system presented here, 424 bp of the human CEACAM5/CEA
promoter are used to drive the expression of the SV40 TAg
antigen. Tumors develop in 100% of the animals in the antrum of
the stomach [12] which were first tentatively identified as
adenocarcinomas due to the expression of EpCAM and transgenic
CEA [12,13,14]. In this study, immunohistological detection of
chromogranin A and B, presence of high levels of serotonin in the
blood as well electron microscopic analysis clearly demonstrated
a neuroendocrine phenotype of gastric tumors of CEA424-
SV40 TAg mice (Figure 1 and data not shown). In addition,
transcriptome analyses of normal and tumor-bearing antral tissue
revealed the enrichment of typical gene signatures found in human
or murine neuroendocrine tumors. For example, 16 out of 42
genes overexpressed $20-fold in the antrum of 90 day old
transgenic mice encode typical (neuro)endocrine proteins (CHGB,
SCT, SCG2, TPH1, GCG, DLK1, CALCA, RESP18, SNAP25,
GRP). Thus the gastric tumors of these mice exhibit a number of
features that might be helpful to study the role of secreted
substances (like serotonin) in NET syndrome formation as well as
to develop new therapeutic strategies for the treatment of gastric
neuroendocrine tumors.
What is the reason for the apparent overrepresentation of
neuroendocrine tumors in SV40 TAg-transgenic mice? One
possibility could be that TAg preferentially transforms neuroen-
docrine progenitor cells. However, this explanation does not apply
Figure 2. The CEA424-SV40 TAg gastric tumor-derived cell line 424GC transcriptome reflects the neuroendocrine phenotype of the
parental tumor. Transcriptome analysis of RNA from tumor-bearing regions of the antrum from 30- (red), 60- (blue) and 90-day-old mice (green)
and d90 non-transgenic mice (pink) as well as from 424GC cells (brown) were performed and the data sets were subjected to hierarchical clustering
and principal component analyses (n=3 for all samples). The heatmap shows that tumors at day 90 and 424GC show the most closely related
expression pattern (A). Note that in PCA, data points of 424GC cells and that of d90 antra exhibit coordinates which are substantially different from
that of all other samples (B). The expression levels (mean of 3 samples and standard deviation) of selected genes (expression ratio d90 antra/normal
antra .15-fold) were compared to that observed for 424GC cells and normal stomach. If a gene was represented by more than one probe set the one
which displayed the highest fold change value (expression d90 versus normal antra) was chosen (C). Note high expression of genes characteristic for
the neuroendocrine lineage in both d90 antra and 424GC cells (e.g. tryptophan hydroxylase, Tph1; chromogranin B, Chgb; secretin, Sct).
doi:10.1371/journal.pone.0029846.g002
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SV40 TAg mouse tumor models with initial TAg expression in
non-neuroendocrine epithelial cells from which neuroendocrine
tumors develop by transdifferentiation [4,9]. Syder et al. directed
expression of TAg to acid-producing parietal cell progenitors of
the stomach using the parietal cell-specific Atp4b promoter. Next to
Figure 3. SV40 T antigen-specific siRNA downregulates expression of neuroendocrine genes in the CEA424-SV40 TAg gastric cancer
cell line 424GC. Three SV40 TAg-targeting siRNAs were evaluated in 424GC cells. siRNA82 and siRNA2047 completely abrogated SV40 T antigen
mRNA expression analyzed 72 h after transient transfection by RT-PCR (A) and Western blot analysis (siRNA82 only; B). The two PCR products
represent both non-spliced and spliced SV40 TAg RNA. The identity of the 70–80 kDa band in the untreated cell sample is unclear. 72 h after addition
of siRNA82 the transcriptome of 424GC cells was analyzed and compared to that of untreated cells. The expression levels of genes up- (negative
ratios) or downregulated (positive ratios) by SV40 T antigen siRNA treatment were plotted against their expression ratio (C). The most strongly up-
and downregulated and most highly expressed genes in the samples are identified by gene symbols and color codes (green, neuroendocrine; red,
cell cycle/proliferation; purple, retroviral; blue, other genes). For comparison, the expression levels and fold chance values of all ribosomal protein
genes were plotted. Note their low fluctuation of expression change (maximally 2-fold). The mean fold change (transcript level with/transcript level
without siRNA treatment) for 244 probe sets was 1.0760.25. The control experiment was performed trice (n=3), the siRNA experiment twice (n=2).
GSEA of the SV40 TAg siRNA ranked gene list from treated and untreated 424GC cells using a neuroendocrine signature of 39 genes from human
tumors as in Figure 1 ([15]; D) and 36 E2F target genes ([19]; E). ES, enrichment score; FDR, false discovery rate; TAg siRNA up/down, signature gene
sets up- or downregulated in TAg siRNA-treated cells.
doi:10.1371/journal.pone.0029846.g003
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neuroendocrine tumors develop after a long latency period of
more than 300 days. Similarly, Czeh et al. observed both well
differentiated adenocarcinomas expressing the epithelial marker
EpCAM and faster proliferating compact synaptophysin-positive
neuroendocrine tumors in the colon of Villin-Cre-ER
T26LoxP-
TAg mice after more than one year. Thus transdifferentiation
appears to be a slow process possibly involving tedious remodeling
of epigenetic modifications. Such is observed during reprogram-
ming of adult cells to induced pluripotent stem cells (iPS) which
can take several weeks [22]. On the other hand, most of the sparse
TAg-positive tumor cells observed in 19- and 30-day-old CEA424-
SV40 TAg mice already express neuroendocrine markers but no
mucins as shown in 30-day-old transgenic mice (data not shown
and Figure 1, Figure S1). We interpret these data as an indication
that there is no direct transit from TAg-positive mucus-producing
progenitor cells to cells expressing neuroendocrine markers
beyond day 30 of development. In 19-day-old mice, single TAg-
positive cells are found near the bottom of the gastric unit or close
to the +4 position which is thought to harbor stem cells and gastric
progenitor cells, respectively (E. V. and W. Z., unpublished results;
[23]). These cells could more rapidly differentiate into cells
committed to the neuroendocrine lineage alleviating the need for
an extended period of time for the development of neuroendocrine
tumors in this model. Despite the pronounced differences in
kinetics and number of possible differentiation steps involved in
the acquisition of the neuroendocrine phenotype, invasive tumors
in both CEA424-SV40 TAg and ATP4b-SV40 TAg mice share a
surprisingly similar neuroendocrine gene expression signature
(Syder signature [4]) including a set of common transcription
factors. Interestingly, in both models, invasive gastric carcinomas
share expression of the transcriptional regulator gene Etv1 which
has recently been shown to encode a master regulator in
neuronally derived GIST tumors and is commonly affected by
gene translocations in prostate tumors which often exhibit a
neuroendocrine phenotype upon progression [18,24,25].
But, why do not all SV40 TAg models develop neuroendocrine
tumors? This might be due to expression of TAg in cells with a
rapid turn-over which would not leave enough time for
transdifferentiation. Indeed, in Fabp2/I-FABP-SV40 TAg mice
mainly hyperplasia is observed [19]. In this model TAg enforces
the reentry of intestinal enterocytes into the cell cycle and induces
suppression of apoptosis by inactivation of RB and p53,
respectively. Similarly, when Apc, a key gatekeeper of intestinal
tumorigenesis, is deleted in short-lived transit-amplifying cells in
colonic crypts using Ah-Cre6loxP-Apc mice, the growth of the
induced microadenomas rapidly subsides while inactivation of Apc
in long-lived colonic stem cells leads to persistent adenomas [26].
Preferential induction of the neuroendocrine phenotype is
possibly not restricted to SV40 TAg. Most interestingly,
epidemiological and molecular genetic studies demonstrated a
high prevalence (80%) of a recently discovered human poly-
omavirus (Merkel cell polyomavirus, MCPyV) in Merkel cell
carcinomas, a rare aggressive skin tumor with epithelial and
neuroendocrine features [27,28]. MCPyV, like the related SV40
virus, encodes a large T antigen which has been shown to bind to
the RB protein and is needed for the maintenance of the growth
capability of the Merkel carcinoma cells [29]. It is assumed that
MCPyV TAg also inactivates the function of both p53 and RB as
it is known for the large T antigen of SV40 TAg.
To analyze whether TAg might be more directly involved in
establishment of the neuroendocrine phenotype we downregu-
lated TAg expression by siRNA in TAg-expressing 424GC gastric
cancer cells. As expected, classical E2F target genes (Cantalupo
E2F gene signature [19]) were downregulated after TAg
depletion and concomitant relief of RB repression. Notably, the
expression of genes found to be typically active in neuroendocrine
tumors (Hofsli gene signature [15]) were also significantly
diminished in 424GC cells, including genes encoding neuroen-
docrine markers such as chromogranin A, dopa decarboxylase
(DDC) and TPH1. The mRNA of the transcriptional regulator
gene Hey1 known to be under E2F control [20] was also
significantly reduced by TAg siRNA and thus could possibly
convey changes in expression of genes encoding neuroendocrine
factors. However, mRNA levels of other transcription factor
genes which regulate the neuroendocrine lineage, like Nkx2.2 and
Neurod1, were not significantly altered by TAg siRNA. Thus the
mechanism of downregulation of neuroendocrine gene signature
remains unclear.
The neuroendocrine phenotype observed recurrently in tumors
of SV40 TAg-transgenic mice suggests that simultaneous inacti-
vation of p53 and RB proteins, a hallmark of SV40 TAg action,
favors the development of neuroendocrine tumors. Indeed, tumors
with neuroendocrine features predominantly develop in genetical-
ly manipulated mouse strains where Trp53 and Rb family genes
have been inactivated. For example, after conditional inactivation
of Trp53 and Rb and optionally of the Rb-related gene p130 in
lung epithelia by application of Cre recombinase-expressing
adenoviral vectors, mice succumbed to neuroendocrine lung
tumors [30]. A set of 23 genes most strongly overexpressed in
lung tumors of double- as well as in triple-mutant mice in
comparison to normal lung tissue are also overexpressed both in
human small cell lung carcinomas which also display a
neuroendocrine phenotype and in CEA424-SV40 TAg gastric
tumors as shown by GSEA (Table 1). Among others, those genes
encode typical neuroendocrine markers like CHGA, CHGB,
DDC and CALCA [30]. Most interestingly, this neuroendocrine
gene signature is also significantly downregulated by TAg siRNA
treatment in 424GC cells (Table 1). This suggests that p53 and RB
play a decisive role in the establishment of the neuroendocrine
phenotype in 424GC cells. Furthermore, specific conditional
ablation of both Rb and Trp53 in osteoblast precursors using an
osterix promoter-Cre deleter strain induced in 75% of the double
knock-out mice metastatic osteosarcomas but, most remarkable, in
60% of the mice metastatic neuroendocrine tumors were detected
as well [31]. In addition, inactivation of both tumor suppressor
genes in prostate epithelium based on a composite rat probasin
promoter-driven Cre expression resulted in rapidly growing
invasive and metastatic prostate carcinomas showing both luminal
epithelial and neuroendocrine differentiation [32]. Interestingly,
high frequency of simultaneous loss of p53 and RB1 alleles is
regularly observed in human small cell lung carcinomas as well as
in large cell neuroendocrine carcinomas of the lung, which are
both tumors with neuroendocrine marker expression [33]. Thus
induction of the neuroendocrine phenotype could also be linked to
the loss of the tumor suppressors p53 and RB1 in human tumors.
However, loss of Trp53 and Rb gene function is not always
associated with the neuroendocrine tumor phenotype. Targeted
deletion of these two genes in stem/bipotent progenitors of breast
epithelia using mouse mammary tumor virus LTR-driven Cre
expression led to histologically uniform, aggressive breast tumors
with an epithelial to mesenchymal transition (EMT) phenotype
[34]. Furthermore, deletion of both tumor suppressor genes in
mesenchymal limb bud cells induced sarcomas in mice [35,36].
This might hint towards tissue specificity of the action of p53 and
Rb and/or involvement of additional SV40 TAg target genes on
top of Trp53 and Rb, like the p300 gene in the generation of
neuroendocrine tumors [1].
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Taken together, strong evidence has accumulated that simul-
taneous inactivation of p53 and RB either by TAg or genetic
alterations can transform cells of various cell lineages, often of
epithelial origin, into tumor cells with neuroendocrine character-
istics. Although less likely, preferential expression of SV40 TAg or
selective sensitivity of neuroendocrine progenitor cells towards
SV40 TAg action cannot be rigorously excluded. To clarify these
issues, more defined conditional murine models are needed which
allow reproducible targeting of stem cells, progenitor cells or
differentiated cells in adult mice using e.g. loxP-SV40 TAg mice in
combination with cell type-specific knock-in Cre-ER
T2 deleter
strains [26,37].
Methods
Ethics statement
All animal work has been conducted according to relevant
national and international guidelines. Animal studies within this
work were registered with and accredited by the local regulatory
agency (Regierung von Oberbayern, Munich, Germany) with
registration number G91.
Mice
The CEA424-SV40 TAg mice [12] were kept and bred at the
animal facility of the Walter Brendel Centre of Experimental
Medicine, Munich, Germany. They were maintained hemizy-
gously on a C57BL/6 background.
Size determination of tumors
Stomachs were opened along the small curvature, flushed with
ice-cold PBS, pinned with needles to a cork disk, fixed in PBS-
buffered 4% formaldehyde for 2 h at room temperature,
dehydrated and soaked in paraffin wax. The stomachs were
sectioned in 4 stripes of equal width along the anterior/posterior
axis, which were paraffin wax embedded after clock-wise rotation
for 90u. Tissue sections were periodic acid Schiff (PAS) stained to
reveal the PAS negative tumors. Tumor area was determined
using the AxioVision Digital Image Processing Software (Carl
Zeiss MicroImaging GmbH, Jena, Germany) and displayed as
mean 6 SD.
Tumor Cell Lines
The cell lines 424GC, mGC3 and mGC8 that were used in this
study have been generated earlier from tumors of CEA424-SV40
TAg mice [13]. The cells were grown in RPMI1640 with sodium
pyruvate, non-essential amino acids, glutamine, 50 mM 2-mercap-
toethanol, 10% fetal bovine serum (Lonza, Cologne, Germany).
The murine endothelioma cell line bEnd.3 was obtained from D.
Vestweber, MPI Mu ¨nster) and cultured as above.
Western Blot
Cells and tumor tissue were lysed in RIPA buffer with protease
inhibitors (Complete Mini, Roche Penzberg, Germany). Protein
concentrations were measured using the Bradford assay (Bio-Rad
Laboratories GmbH, Munich, Germany). Equal protein amounts
(100 mg per sample) were separated on 8–16% sodium dodecyl
sulfate polyacrylamide gels (Thermo-Fisher, Bonn, Germany) by
electrophoresis followed by transfer to nitrocellulose. Membranes
were probed with either a monoclonal rabbit anti-NEUROD1
antibody (# 4373, New England Biolabs/Cell Signaling, Frank-
furt, Germany), polyclonal rabbit antibodies against SV40 TAg
(sc-20800; Santa Cruz, Heidelberg, Germany) or a rabbit anti-b-
actin (sc-1616, Santa Cruz) followed by incubation with a horse
radish peroxidase (HRP)-tagged anti-rabbit IgG antibody (New
England Biolabs/Cell Signaling). For HRP detection SuperSignal
West Pico Chemiluminescent Substrate (Thermo-Fisher) was used
according to the supplier’s protocol.
ELISA
Serotonin concentrations were measured in EDTA plasma by a
competition ELISA (IBL, Hamburg, Germany) according to the
manufacture’s protocol.
Immunohistochemistry and immunofluorescence
Stomachs were fixed and embedded as above. Serial sections
were dewaxed and stained with the appropriate antibodies after
heat retrieval of the antigens at pH 9.0 (Target Retrieval Solution;
Dako Deutschland GmbH, Hamburg, Germany). The tissue
sections were reacted with primary antibodies that were visualized
using HRP-coupled secondary antibodies and 3-amino-9-ethyl-
carbazole as substrate (ImmPRESS Anti-Rabbit Ig Polymer
Detection Kit; Vector Labs, Burlington, Ontario, Canada).
Sections were counterstained with hematoxylin and viewed with
a Nikon Eclipse E800 microscope and photographed using a
Nikon DS-5M-L1 digital camera. For immunofluorescence, tissue
sections were blocked for 20 min in 2.5% horse serum. Incubation
with primary antibody was at 4uC overnight or at room
temperature for 2 h. After washing with PBS, secondary
antibodies, conjugated to Alexa-568 or Alexa-647 (Invitrogen)
were added for 1 h at room temperature. Sections were
counterstained with DAPI (0.5 mg/ml) and mounted in Dako
Mounting Medium (Dako). Imaging was performed with a Leica
DM IRBE scanning confocal microscope or a Zeiss Axiophot
microscope. The following primary antibodies were used:
polyclonal goat antibodies against chromogranin A (1:200; sc-
1488; Santa Cruz), polyclonal rabbit antibodies against SV40 TAg
(1:500; sc-20800; Santa Cruz). After SV40 TAg detection by
immunohistochemistry mucin-secreting cells were stained by
incubation with 1% Alcian blue/3% acetic acid solution pH 2.5
for 30 min.
Electron microscopy
Tumor samples (0.5 to 1 mm
3 pieces) were immersed in 3.5%
glutardialdehyde. Post-fixation treatment was performed in 1%
OsO4 containing 1.5% K4Fe(CN)6 in 0.1 M cacodylate buffer for
1 h. After dehydration and embedding in Araldite (SERVA
Electrophoresis GmbH, Heidelberg, Germany) sections were cut
on a Leica Ultracut UCT ultramicrotome and examined in a Zeiss
EM 900 transmission electron microscope.
RNA isolation and reverse transcription PCR
Total RNA was isolated from tissue and cell samples using the
NucleoSpin RNA II kit (Macherey-Nagel, Du ¨ren, Germany)
according to the manufacturer’s protocol. Standard protocols were
applied for reverse transcription of RNA and detection of SV40
TAg cDNA by PCR. The following forward and reverse primers
which flank the intron present in the SV40 TAg gene were used:
59-AATTCTGAAGGAAAGTCCTTGG, 59- TAATGGACCT-
TCTAGGTCTTGA.
Microarray analysis
To characterize the gene expression profile in the stomach three
mice each at an age of 30, 60 or 90 days were sacrificed. Tissues
were taken from the antrum of the stomach where tumor lesions
were visible macroscopically by the age of 60 days. Tissues from
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used as control. Total RNA was isolated as described above.
Biotinylated cRNA was prepared with the IlluminaH TotalPrep
TM
RNA Amplification Kit (Applied Biosystems, Darmstadt, Ger-
many). cRNA (1.5 mg) was hybridized to Sentrix Mouse-6
Expression Beadchips (Illumina, San Diego, CA) and scanned
on Illumina BeadStation 5006. For data collection Illumina
BeadStudio software was used. The data were normalized using R
Statistical language and packages from the Bioconductor project as
well as the vsn normalization method [38]. Microarray data
comply with MIAME guidelines and are available at http://www.
ncbi.nlm.nih.gov/geo (accession no. GSE27712). Microarray data
were analyzed for enrichment of preselected gene sets by Gene Set
Enrichment Analysis (GSEA), developed by the Broad-Institute,
Cambridge, MA 02141, USA (http://broad.harvard.edu/gsea/)
[39,40]. Differentially expressed genes were assessed by applying t-
test with p,0.05, fold change (fc) filters (fc $2) and difference of
means .100 using dChip software. For this purpose microarray
raw data of the respective samples were normalized using quantiles
normalization. Hierarchical clustering and principal component
analysis (PCA) was performed based on genes differentially
expressed between controls and 90-day-old transgenic mice (t-test
with p,0.05, fc $2, difference of means .100 and passing 10%
false discovery rate).
siRNA experiments
Exponentially growing cells were transfected with siRNA using
Lipofectamine
TM (Invitrogen GmbH; Darmstadt, Germany).
SV40 TAg-specific siRNA was designed using the BLOCK-iT
TM
RNAi Designer (Invitrogen). Three Stealth RNAi siRNA sequenc-
es were tested at different concentration and finally used at
600 nM in the experiments. After 24, 48 and 72 h, cells were lysed
for protein analysis as described. For gene expression analysis
RNA was isolated after 72 h as described above. RNA isolation
and microarray analysis was performed as described above. Data
were normalized using the quantile normalization method.
Microarray data are available at http://www.ncbi.nlm.nih.gov/
geo (accession no. GSE27712).
Statistical analysis
Experimental data were analyzed by Sigma plot for Windows,
Version 10.0 (Systat Software Inc., San Jose, USA) using Student’s
t-test. P-values of p,0.05 were considered as statistically
significant.
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